JOURNAL ARTICLE
RESEARCH SUPPORT, NON-U.S. GOV'T
Add like
Add dislike
Add to saved papers

Aldehyde dehydrogenase-1 is a specific marker for stem cells in human lung adenocarcinoma.

To investigate whether aldehyde dehydrogenase-1 (ALDH-1) in human lung cancer can be used as a sorting marker for stem cells in targeted therapies against human lung cancer. Spheres were induced by incubating cancer cells in a serum-free medium and formed with epidermal growth factor and fibroblast growth factor-10 (FGF10). Spheroid cells were combined with flow cytometry using the Aldefluor reagent to separate the SSCloALDEbr (ALDH-1-positive) cells. Cancer stem cells (CSCs) were characterized by their proliferation, colony formation, and tumorigenesis in nude mice and using phenotypic analysis. Float-growing spheres ("pulmospheres") were developed after SPC-A1 cells were cultured in a serum-free medium. The resultant sphere-forming cells included ALDH-1-positive cells as high as 15.13%. ALDH-1-positive CSCs have high proliferative ability, high cloning efficiency, and strong tumorigenicity. The rate of SSC(lo)ALDE(br) cell colony formation was 1.3-5.6%, whereas that of ALDE(-) cell colony formation was only 0-1.2% (P < 0.05). A cell count of only 1 × 10(3) SSC(lo)ALDE(br) cells was necessary to form tumors, whereas at least l × 10(5) ALDE(-) cells formed tumors. The same number of SSC(lo)ALDE(br) cells also formed larger tumors in a short latency period of tumor formation. The expression rates of CD133 in the SSC(lo)ALDE(br) and ALDE(-) cells were 16.31% (16.31 × 10(4)/10(6)) and 2.56% (2.56 × 10(4)/10(6)), respectively (P < 0.01). Moreover, the expression rates of ABCG2 in SSC(lo)ALDE(br) and ALDE(-) cells were 17.62% (17.62 × 10(4)/10(6)) and 3.45% (3.45 × 10(4)/10(6)), respectively (P < 0.01). Human lung adenocarcinoma bears CSCs, and ALDH-1 can act as a specific marker for human lung CSCs.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app